First patient randomised in a phase 3 study evaluating safety and efficacy of anakinra in the treatment of Still’s disease

Swedish Orphan Biovitrum AB (publ)  (Sobi™) announces that the first patient has been randomised in the phase 3 study anaSTILLs, to evaluate efficacy and safety of anakinra in the treatment of Still’s disease. The purpose of the study is to assess the efficacy and to evaluate the safety of anakinra in patients with newly diagnosed Still’s disease, including systemic juvenile idiopathic arthritis (SJIA) and adult onset Still’s disease (AOSD). The anaSTILLs study is a randomised, double-blind, multicentre study being conducted in North America studying two dose levels